Targeted hormone therapy for breast cancer.
Large-scale studies now provide relatively clear guidelines for the clinician on antiestrogen treatment in various patient populations and subgroups. Future challenges are to determine whether antiestrogens might be used for prevention, to identify the environmental and genetic causes of breast cancer, and to develop new approaches to this tumor, such as antiprogestins.
Jordan
V C
VC
Breast Cancer Program, University of Wisconsin Comprehensive Cancer Center, Madison.
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant / Q000379:methods / Q000592:standards; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008593:Menopause; D051379:Mice; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D051381:Rats; D011960:Receptors, Estrogen / Q000032:analysis / Q000187:drug effects; D015996:Survival Rate; D013629:Tamoxifen / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011960:Receptors, Estrogen; D013629:Tamoxifen